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Abstract
The European Committee on Antimicrobial Susceptibility Testing Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST) has
determined breakpoints for voriconazole against Aspergillus spp. This Technical Note is based on the EUCAST rationale document for
voriconazole (available on the EUCAST website: http://www.eucast.org). Voriconazole breakpoints are based on epidemiological cut-off
values, pharmacokinetic/pharmacodynamic data and clinical experience. Breakpoints will be reviewed regularly or when new data emerge.
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Abstract
Although internal medicine wards (IMWs) represent a significant reservoir of patients with candidemia, few investigators have specifically
addressed the epidemiological aspects of candidaemia in this population. Of all patients hospitalized during the study period with candidaemia,
133/348 (38%) were admitted to IMWs. Variables associated with IMWs included: antibiotic therapy prior to hospitalization, urinary or central
venous catheter, parenteral nutrition, tumour and age >75 years. Overall, 30-day mortality in IMWs was significantly higher than that in other
wards (51.1% vs. 38.2%, p <0.02).Multiple logistic regression analysis identified the administration of antifungal treatment 48 h after having the
first positive BC as an independent determinant of hospital mortality.Patients with candidaemia in IMWs account for a substantial proportion of
patients with candidaemia and have higher mortality compared with patients in other wards.
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